Regeneron Pharmaceuticals, Inc. $REGN Position Lessened by Ellerson Group Inc. ADV

Ellerson Group Inc. ADV reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 33.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,431 shares of the biopharmaceutical company’s stock after selling 2,711 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 2.0% of Ellerson Group Inc. ADV’s holdings, making the stock its 22nd largest position. Ellerson Group Inc. ADV’s holdings in Regeneron Pharmaceuticals were worth $2,851,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in REGN. Vanguard Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after acquiring an additional 121,545 shares during the period. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock worth $1,379,467,000 after purchasing an additional 89,579 shares during the last quarter. Amundi grew its position in Regeneron Pharmaceuticals by 3.4% in the 1st quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock worth $979,794,000 after purchasing an additional 52,166 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 18.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after purchasing an additional 174,056 shares during the period. Finally, American Century Companies Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2.1% during the first quarter. American Century Companies Inc. now owns 722,467 shares of the biopharmaceutical company’s stock valued at $458,211,000 after buying an additional 14,921 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 0.4%

Shares of Regeneron Pharmaceuticals stock opened at $654.74 on Tuesday. The business has a fifty day simple moving average of $589.52 and a 200-day simple moving average of $568.29. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $834.42. The firm has a market cap of $69.39 billion, a price-to-earnings ratio of 15.68, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same period in the previous year, the company earned $12.46 earnings per share. Regeneron Pharmaceuticals’s revenue was up .9% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $580.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 29th. Sanford C. Bernstein raised their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $796.57.

Insider Buying and Selling

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.